Lack of effect of motivation on the adherence of HIV-positive/AIDS patients to antiretroviral treatment

Brazilian Journal of Infectious Diseases

Volumn 9, Issue 6, 2005, Pages 494-499

  Garcia, Rosa ^a,c   Pondé, Milena ^a   Lima, Manuela ^a   De Souza, Alba Regina ^b   Stolze, Silvia Maria De O ^b   Badaró, Roberto ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b CREAIDS   (Brazil)

^c CREAIDS ^*  (Brazil)

Author keywords

Adherence; HIV Positive AIDS; Motivation; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MOTIVATION; PATIENT COMPLIANCE; VIRUS LOAD;

EID: 31144438821     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702005000600007     Document Type: Article

References (24)

1. Singh N., Bernab S.M., Swindells S., et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824-30.
2. Tuldra A., Ferrer M.J., Fumaz C.R., et al. Monitoring adherence to HIV therapy. Arch Intern Med 1999;159:1376-7.
3. Hecht F.M. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998;10:57-9.
4. Moyer T.P., Temesgen Z., Enger R., et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method of validation and results of a pilot study. Clin Chem 1999;45:1465-76.
5. th ICAAC, San Diego, CA, 1998.
6. Friedland G.H. Adherence: The Achilles' heel of highly active antiretroviral therapy. IAS-USA 1997;5(1):3-15.
7. th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1998. (Abstract 419).
8. th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria VA.: Foundation for Retrovirology and Human Health, 1999; 84:
9. Lamotte C, Peytavin G, Farinotti R. Determination of Nelfinavir, a potent protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode array detection. J Chromatogr B Biomed Sci Appl 1999;735:159-70.
10. Cramer J.A., Mattson R.H., Prevey M.L., et al. How often is modification taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-277.
11. Mostashari F., Riley E., Sclwyn P.A., Altice EL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Aquir Immune Defic Syndr Hum Retroviral 1998;18:341-8.
12. Tamayo A., Schwartz S. Estrutura Motivacional dos Valores Humanos, Psic Teor Pesq, Brasília 1993;(9)No.2:329-48.
13. a Conferência Anual Brasil AIDS. Universidade John Hopkins hopkins-aids.edu/educational/events/brazil 2000.
14. Yerly S., Kaiser L., Race E., et al. Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet 1999;354:729-33.
15. Little S.J., Daar E.S., D'aquila R.T., et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. J Am Med Assoc 1999;282:1142-9.
16. th Conference on Retroviruses and Opportunistic Infections. Chicago: Abstract LB8, 1999.
17. Murphy R.L., Brun S., Hicks C., et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001;15:p. F1-9.
18. th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. (Abstract 57).
19. Mokrzycki M.H., Harris C., May H., et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis, 2000;30:198-200.
20. Dube M.P. Metabolic complications of antiretroviral therapies. AIDS Clinical Care, 1998.10: p. 41.
21. Eastone J.A., Decker C.F. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997;127:948.
22. Visnegarwala F., Krause K.L., Musher D.M. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.
23. Ter Hofstede H.J., de Marie S., Foudraine N.A., et Al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000;11:611-6.
24. Lorenzi P., Yerly S., Abderrakim K., et al. Toxicity, efficacy, plasma drug concentration and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997;1:F95-9.